
    
      A Non Interventional, open-label, single arm, single institution pilot study. Eligible
      patients will be monitored by diffusion-weighted magnetic resonance tomography (dMRT) during
      treatment with bevacizumab + chemotherapy for up to four cycles followed by bevacizumab
      maintenance therapy until disease progression.
    
  